Porton Advanced and Ascle Therapeutics Have Established a Strategic Partnership to Enhance the Utilization of NK Cells in Cancer Prevention, Beauty, and Anti-aging

Porton Advanced and Ascle Therapeutics have recently announced a strategic partnership, focusing on joint efforts in the development and production of NK cells. The collaboration extends to advancing innovation in gene and cell therapy, with a particular emphasis on accelerating the application of NK cells in areas such as cancer prevention, beauty, and anti-aging.

Porton Advanced is dedicated to providing comprehensive gene and cell therapy CDMO (Contract Development and Manufacturing Organization) services, spanning various domains such as plasmids, cell therapy, gene therapy, and mRNA therapy. Currently, the company has successfully supported clients in completing CMC (Chemistry, Manufacturing, and Controls) and global declaration services for multiple gene and cell therapy drugs.

Ascle Therapeutics specializes in groundbreaking immune cell therapy products, particularly in the NK/CAR-NK anti-tumor immune cell therapy drugs. The company has established a robust immune cell therapy research and production system, boasting three major technology platforms: universal CAR-NK, allogeneic NK/CAR-NK, and mRNA-LNP.

According to the partnership agreement, Porton Advanced will provide development, production, and declaration services in China for Ascle Therapeutics' NK cell project. This collaboration aims to bolster the application of NK cells in cancer prevention, anti-aging, and beauty.

Ascle Therapeutics, emphasized the significant impact of CAR-NK cell therapy on cancer treatment. This genetic engineering approach enhances NK cells' ability to identify and eliminate tumor cells while minimizing harm to normal cells. Dr. Li also highlighted the remarkable efficacy of NK cells in anti-aging, with a single dose showing substantial reduction in circulating senescent cells for an extended period.

Porton Advanced, expressed enthusiasm about the strategic partnership, emphasizing Ascle Therapeutics' deep expertise in the NK field. Porton Advanced, with its end-to-end gene and cell therapy CDMO platform, is well-equipped to provide crucial support for Ascle Therapeutics' NK cell projects. Dr. Wang highlighted Porton Advanced's advanced capabilities in process development, sterile drug production, and adherence to international production and inspection standards.

The partnership is expected to facilitate swift progress in Ascle Therapeutics' NK cell projects related to anti-aging, beauty, and cancer prevention, leveraging Porton Advanced's expertise and infrastructure.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!